NEW YORK – Genomics analysis firm Variantyx said on Monday that it has raised $41.5 million in a Series C-2 funding round.
New Era Capital Partners led the round, joined by Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech.
In a statement, the company said it will use the funding to grow and to launch its whole-genome analysis technology, with a focus on precision oncology.
Framingham, Massachusetts-based Variantyx has expanded into oncology and prenatal testing after launching in 2014 as a clinical decision support engine. The company, which raised at least $26 million in Series C financing last year, has licensed genomic analysis technology from Israel's Tel Aviv University.